Fize Medical, Inc., a Miami, Florida-based medical device company raised $ 3.3 million and closed a $ 5.3 million Series A financing.
The round was led by Rapha Capital Management, LLC and MIG FZ LLC, with the participation of the first venture capital fund managed by Rapha Capital, Rapha Capital BioVentures Fund I.
The company intends to use the funds to continue the development and commercialization of its new device, the iUO ™, an automatic, digital and cost-effective device for measuring urine flow in real time, replacing the urinometer bag. current, manually managed, attached to a standard Foley catheter, which will be made available to hospitals and physicians around the world.
Led by Dror Zerem, CEO, FIZE Medical is developing a testing platform to measure key patient health indicators found in their urine, in real time, delivered via iUO ™, iUO PLUS ™ and iUO devices DUOFLO ™. The basic FIZE® device, iUO ™, measures urine output in real time in a fully automated fashion and integrated with current healthcare computing platforms such as the EMR. The company’s product line provides a complete solution by extracting all additional relevant clinical information from urine and delivering it to clinicians at their fingertips.